Ketamine for the Treatment of Depression in Patients Receiving Hospice Care: A Retrospective Medical Record Review of Thirty-One Cases

Alana Iglewicz, Katherine Morrison, Richard A. Nelesen, Tingting Zhan, Boris Iglewicz, Nathan Fairman, Jeremy M. Hirst, Scott A. Irwin

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Depression is prevalent in patients receiving hospice care. Standard antidepressant medications do not work rapidly enough in this setting. Evidence suggests that ketamine rapidly treats treatment refractory depression in the general population. Ketamine's role for treating depression in the hospice population warrants further study. Methods: A retrospective medical record review of 31 inpatients receiving hospice care who received ketamine for depression on a clinical basis was conducted. The primary outcome measure was the Clinical Global Impression Scale, which was used retrospectively to rate subjects' therapeutic improvement, global improvement, and side effects from ketamine over 21 days. Additionally, time to onset of therapeutic effect was analyzed. Results: Using the Clinical Global Impression Scale, ketamine was found to be significantly therapeutically effective through the first week after ketamine dosing (p < 0.05), with 93% of patients showing positive results for days 0-3 and 80% for days 4-7 following ketamine dosing. Patients experienced global improvement during all 4 studied time periods following ketamine dosing (p < 0.05). Significantly more patients had either no side effects or side effects that did not significantly impair functioning at each of the 4 assessed time periods following ketamine dosing (p < 0.05). Additionally, significantly more patients experienced their first therapeutic response during days 0-1 following ketamine dosing (p < 0.001) than during any other time period. Conclusions: These data suggest that ketamine may be a safe, effective, and rapid treatment for clinical depression in patients receiving hospice care. Blinded, randomized, and controlled trials are required to substantiate these findings and support further clinical use of this medication in hospice settings.

Original languageEnglish (US)
Pages (from-to)329-337
Number of pages9
JournalPsychosomatics
Volume56
Issue number4
DOIs
StatePublished - Jul 1 2015

Fingerprint

Hospice Care
Ketamine
Medical Records
Depression
Therapeutics
Hospices
Hospice
Treatment-Resistant Depressive Disorder
Therapeutic Uses
Antidepressive Agents
Population
Inpatients
Randomized Controlled Trials
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Applied Psychology
  • Arts and Humanities (miscellaneous)

Cite this

Ketamine for the Treatment of Depression in Patients Receiving Hospice Care : A Retrospective Medical Record Review of Thirty-One Cases. / Iglewicz, Alana; Morrison, Katherine; Nelesen, Richard A.; Zhan, Tingting; Iglewicz, Boris; Fairman, Nathan; Hirst, Jeremy M.; Irwin, Scott A.

In: Psychosomatics, Vol. 56, No. 4, 01.07.2015, p. 329-337.

Research output: Contribution to journalArticle

Iglewicz, Alana ; Morrison, Katherine ; Nelesen, Richard A. ; Zhan, Tingting ; Iglewicz, Boris ; Fairman, Nathan ; Hirst, Jeremy M. ; Irwin, Scott A. / Ketamine for the Treatment of Depression in Patients Receiving Hospice Care : A Retrospective Medical Record Review of Thirty-One Cases. In: Psychosomatics. 2015 ; Vol. 56, No. 4. pp. 329-337.
@article{63a7ee149b154b88bd19e04bf375782f,
title = "Ketamine for the Treatment of Depression in Patients Receiving Hospice Care: A Retrospective Medical Record Review of Thirty-One Cases",
abstract = "Background: Depression is prevalent in patients receiving hospice care. Standard antidepressant medications do not work rapidly enough in this setting. Evidence suggests that ketamine rapidly treats treatment refractory depression in the general population. Ketamine's role for treating depression in the hospice population warrants further study. Methods: A retrospective medical record review of 31 inpatients receiving hospice care who received ketamine for depression on a clinical basis was conducted. The primary outcome measure was the Clinical Global Impression Scale, which was used retrospectively to rate subjects' therapeutic improvement, global improvement, and side effects from ketamine over 21 days. Additionally, time to onset of therapeutic effect was analyzed. Results: Using the Clinical Global Impression Scale, ketamine was found to be significantly therapeutically effective through the first week after ketamine dosing (p < 0.05), with 93{\%} of patients showing positive results for days 0-3 and 80{\%} for days 4-7 following ketamine dosing. Patients experienced global improvement during all 4 studied time periods following ketamine dosing (p < 0.05). Significantly more patients had either no side effects or side effects that did not significantly impair functioning at each of the 4 assessed time periods following ketamine dosing (p < 0.05). Additionally, significantly more patients experienced their first therapeutic response during days 0-1 following ketamine dosing (p < 0.001) than during any other time period. Conclusions: These data suggest that ketamine may be a safe, effective, and rapid treatment for clinical depression in patients receiving hospice care. Blinded, randomized, and controlled trials are required to substantiate these findings and support further clinical use of this medication in hospice settings.",
author = "Alana Iglewicz and Katherine Morrison and Nelesen, {Richard A.} and Tingting Zhan and Boris Iglewicz and Nathan Fairman and Hirst, {Jeremy M.} and Irwin, {Scott A.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.psym.2014.05.005",
language = "English (US)",
volume = "56",
pages = "329--337",
journal = "Psychosomatics",
issn = "0033-3182",
publisher = "American Psychiatric Publishing Inc.",
number = "4",

}

TY - JOUR

T1 - Ketamine for the Treatment of Depression in Patients Receiving Hospice Care

T2 - A Retrospective Medical Record Review of Thirty-One Cases

AU - Iglewicz, Alana

AU - Morrison, Katherine

AU - Nelesen, Richard A.

AU - Zhan, Tingting

AU - Iglewicz, Boris

AU - Fairman, Nathan

AU - Hirst, Jeremy M.

AU - Irwin, Scott A.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background: Depression is prevalent in patients receiving hospice care. Standard antidepressant medications do not work rapidly enough in this setting. Evidence suggests that ketamine rapidly treats treatment refractory depression in the general population. Ketamine's role for treating depression in the hospice population warrants further study. Methods: A retrospective medical record review of 31 inpatients receiving hospice care who received ketamine for depression on a clinical basis was conducted. The primary outcome measure was the Clinical Global Impression Scale, which was used retrospectively to rate subjects' therapeutic improvement, global improvement, and side effects from ketamine over 21 days. Additionally, time to onset of therapeutic effect was analyzed. Results: Using the Clinical Global Impression Scale, ketamine was found to be significantly therapeutically effective through the first week after ketamine dosing (p < 0.05), with 93% of patients showing positive results for days 0-3 and 80% for days 4-7 following ketamine dosing. Patients experienced global improvement during all 4 studied time periods following ketamine dosing (p < 0.05). Significantly more patients had either no side effects or side effects that did not significantly impair functioning at each of the 4 assessed time periods following ketamine dosing (p < 0.05). Additionally, significantly more patients experienced their first therapeutic response during days 0-1 following ketamine dosing (p < 0.001) than during any other time period. Conclusions: These data suggest that ketamine may be a safe, effective, and rapid treatment for clinical depression in patients receiving hospice care. Blinded, randomized, and controlled trials are required to substantiate these findings and support further clinical use of this medication in hospice settings.

AB - Background: Depression is prevalent in patients receiving hospice care. Standard antidepressant medications do not work rapidly enough in this setting. Evidence suggests that ketamine rapidly treats treatment refractory depression in the general population. Ketamine's role for treating depression in the hospice population warrants further study. Methods: A retrospective medical record review of 31 inpatients receiving hospice care who received ketamine for depression on a clinical basis was conducted. The primary outcome measure was the Clinical Global Impression Scale, which was used retrospectively to rate subjects' therapeutic improvement, global improvement, and side effects from ketamine over 21 days. Additionally, time to onset of therapeutic effect was analyzed. Results: Using the Clinical Global Impression Scale, ketamine was found to be significantly therapeutically effective through the first week after ketamine dosing (p < 0.05), with 93% of patients showing positive results for days 0-3 and 80% for days 4-7 following ketamine dosing. Patients experienced global improvement during all 4 studied time periods following ketamine dosing (p < 0.05). Significantly more patients had either no side effects or side effects that did not significantly impair functioning at each of the 4 assessed time periods following ketamine dosing (p < 0.05). Additionally, significantly more patients experienced their first therapeutic response during days 0-1 following ketamine dosing (p < 0.001) than during any other time period. Conclusions: These data suggest that ketamine may be a safe, effective, and rapid treatment for clinical depression in patients receiving hospice care. Blinded, randomized, and controlled trials are required to substantiate these findings and support further clinical use of this medication in hospice settings.

UR - http://www.scopus.com/inward/record.url?scp=84937520979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937520979&partnerID=8YFLogxK

U2 - 10.1016/j.psym.2014.05.005

DO - 10.1016/j.psym.2014.05.005

M3 - Article

C2 - 25616995

AN - SCOPUS:84937520979

VL - 56

SP - 329

EP - 337

JO - Psychosomatics

JF - Psychosomatics

SN - 0033-3182

IS - 4

ER -